Evommune EVMN Weighted Average Numberof Shares Dilutive Effect Of Series B Preferred Stock

Weighted Average Numberof Shares Dilutive Effect Of Series B Preferred Stock at other companies

Falcon's Beyond GlobalFBYD

6.7M—

The BancorpTBBK

42.6M-11.2%

Relay Therapeutics, Inc.RLAY

179.8M+6.3%

BeldenBDC

39.4M-3.5%

StrykerSYK

3.6M-23.4%

Devon EnergyDVN

2M0.0%

Other financials

Income statement

See full

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

See full

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

See full

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

See full

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

See full

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

See full

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept meha:WeightedAverageNumberofSharesDilutiveEffectOfSeriesBPreferredStock.

The official record: Evommune ’s 10-K, filed March 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's weighted average numberof shares dilutive effect of series b preferred stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Evommune 's weighted average numberof shares dilutive effect of series b preferred stock?: Evommune (EVMN) reported weighted average numberof shares dilutive effect of series b preferred stock of 15.1M in Q4 2025.
What does weighted average numberof shares dilutive effect of series b preferred stock mean?: The incremental number of shares that would be issued upon the conversion of Series B preferred stock, factored into the calculation of diluted earnings per share. This metric quantifies the potential dilution risk posed by the Series B preferred equity structure.